New ultrasound test could make liver fat detection quick and painless
NCT ID NCT07270601
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new ultrasound method to measure fat in the liver without needles or expensive scans. It involves 110 adults with or at risk for MASLD, a common liver condition linked to obesity and diabetes. If successful, this tool could make liver health checks easier and more accessible for millions.
Why investors are watching
ContextVision, a micro-cap company, is running a study of an ultrasound-based tool to measure liver fat without a biopsy or MRI. The trial enrolls 110 people with suspected MASLD, a common condition linked to obesity and diabetes. For a company this small, a successful readout could validate its software as a cheaper, accessible diagnostic option.
If it works: A positive result could position ContextVision's ultrasound biomarker as a practical alternative to expensive or invasive liver tests. That could open a path to broader clinical use and new revenue from hospitals or clinics.
If it fails: The study could fail to show the ultrasound tool matches existing methods, or the company could face delays. Trials often fail, and for a micro-cap, a negative result would likely hurt confidence in the product.
AI-written from the trial record. Speculative, and not investment advice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 110 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2025
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Diseased subject: * Adult patients (age 18 - 75 years) * Consent to participate in the study * Diagnosed or suspected MASLD from the hepatology clinic, OR * High-risk population meeting the adult cardiometabolic criteria (defined as the presence of at least one of the following: diabetes, obesity (BMI ≥ 25 kg/m2), hypercholesterolemia, and hypertension) Healthy volunteer: * Adult patients (age 18 - 75 years) * Consent to participate in the study * No suspicion of MASLD by laboratory/imaging/clinical examinations * Absence of known pre-existing conditions (metabolic syndrome, diabetes mellitus, obesity, insulin resistance, dyslipidemia, etc.) Exclusion Criteria: * Pregnancy or nursing. * Contraindications to MRI including, but not limited to, severe claustrophobia, pacemaker, or existing metallic/mechanical implant(s). * Acute illness/cognitive impairment resulting in an inability to cooperate with the MRI and ultrasound breath-holding instructions. * BMI \> 35 kg/m2 * History of excessive alcohol consumption according to the updated MASLD criteria (\>2 drinks/day OR \>210 grams/week for males AND \>1 drink/day OR \>140 grams/week for females) or drug use over the past 2 years. * Known acute or chronic hepatitis; or other etiology of liver disease. * Presence of known congenital hepatic anomaly. * Known cirrhosis * Known active cancer
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Masld (metabolic dysfunction-associated steatotic liver disease) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Washington
RECRUITINGSeattle, Washington, 98195, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a liver risk score predict early death from routine checkups?
- A simple scan and blood test could catch silent liver scarring before It's too late
- A simple body scan may spot fatty liver disease without needles
- Could a common b vitamin tame fatty liver?
- Could a daily dose of citrus fiber tame fatty liver inflammation?
- Could a simple cooking tweak reverse fatty liver? a new trial puts low-AGE foods to the test.